Retatrutide is an investigational medication currently in clinical development, primarily designed for weight loss and metabolic health. It is a triple hormone receptor agonist, meaning it activates three different hormone receptors involved in regulating appetite, digestion, and blood sugar levels.

What Retatrutide Does:

• Targets three hormone receptors: It activates receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple action helps regulate multiple pathways related to metabolism.

• Suppresses appetite: By acting on these receptors, retatrutide reduces hunger and increases feelings of fullness, helping to decrease food intake.

• Slows digestion: It delays gastric emptying, which prolongs satiety after meals.

• Increases fat metabolism: Retatrutide promotes the breakdown of fat, aiding in weight loss.

• Improves blood sugar control: It helps regulate glucose levels, making it potentially useful for managing type 2 diabetes alongside weight loss.

In summary, retatrutide is a promising multi-action peptide drug aimed at effective weight management and metabolic improvement by simultaneously targeting multiple hormonal pathways.